MX2017016188A - FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMí‰RICO. - Google Patents

FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMí‰RICO.

Info

Publication number
MX2017016188A
MX2017016188A MX2017016188A MX2017016188A MX2017016188A MX 2017016188 A MX2017016188 A MX 2017016188A MX 2017016188 A MX2017016188 A MX 2017016188A MX 2017016188 A MX2017016188 A MX 2017016188A MX 2017016188 A MX2017016188 A MX 2017016188A
Authority
MX
Mexico
Prior art keywords
hetero
specific antibody
antibody format
domains
dimeric multi
Prior art date
Application number
MX2017016188A
Other languages
English (en)
Inventor
Urech David
Meyer Sebastian
Original Assignee
Numab Innovation Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Innovation Ag filed Critical Numab Innovation Ag
Publication of MX2017016188A publication Critical patent/MX2017016188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a nuevo formato multiespecí­fico heterodimórico de múltiples dominios variables de anticuerpos que comprenden un núcleo de dos pares de dominios variables divididos en el que tanto los dominios ligeros variables como los dos dominios pesados variables afines están situados en tándem en dos cadenas de proteí­cas separadas, respectivamente.
MX2017016188A 2015-06-15 2016-06-15 FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMí‰RICO. MX2017016188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001758 2015-06-15
PCT/EP2016/001002 WO2016202457A1 (en) 2015-06-15 2016-06-15 Hetero-dimeric multi-specific antibody format

Publications (1)

Publication Number Publication Date
MX2017016188A true MX2017016188A (es) 2018-07-06

Family

ID=53434175

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016188A MX2017016188A (es) 2015-06-15 2016-06-15 FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMí‰RICO.
MX2022011472A MX2022011472A (es) 2015-06-15 2017-12-13 Formato de anticuerpo multiespecifico heterodimerico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011472A MX2022011472A (es) 2015-06-15 2017-12-13 Formato de anticuerpo multiespecifico heterodimerico.

Country Status (13)

Country Link
US (2) US11236150B2 (es)
EP (2) EP3307776A1 (es)
JP (3) JP6839101B2 (es)
KR (1) KR20180012860A (es)
CN (2) CN107922486B (es)
AU (2) AU2016278586B2 (es)
CA (1) CA2989474C (es)
EA (1) EA201890041A1 (es)
HK (1) HK1245805A1 (es)
IL (2) IL293435A (es)
MA (1) MA44381A (es)
MX (2) MX2017016188A (es)
WO (1) WO2016202457A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307776A1 (en) * 2015-06-15 2018-04-18 Numab Innovation AG Hetero-dimeric multi-specific antibody format
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
IL271127B1 (en) 2017-06-05 2024-06-01 Numab Therapeutics AG New anti-HSA antibodies
CN110719918B (zh) * 2017-06-05 2024-05-24 努玛治疗有限公司 靶向至少cd3和hsa的异源二聚体多特异性抗体形式
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
MX2020003562A (es) 2017-10-10 2020-10-01 Numab Therapeutics AG Anticuerpo multiespecifico.
SG11202003111SA (en) 2017-10-10 2020-05-28 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CA3074802A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG Antibodies targeting pdl1 and methods of use thereof
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
CN111836630A (zh) * 2018-01-05 2020-10-27 希望之城 多特异性配体结合物
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
US20220127350A1 (en) 2019-01-31 2022-04-28 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
US20230303698A1 (en) * 2020-06-30 2023-09-28 Harbour Biomed (Shanghai) Co., Ltd Multispecific binding protein of immune cell engager, preparation therefor and application thereof
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
EP4019546A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-31
US20240043547A1 (en) 2020-12-23 2024-02-08 Numab Therapeutics AG Antibody variable domains that bind il-31
WO2022167460A1 (en) 2021-02-02 2022-08-11 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
CN115536749A (zh) 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4273162A1 (en) 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220388A1 (en) * 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
MX342623B (es) 2009-06-26 2016-10-06 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013003652A1 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP6605331B2 (ja) * 2013-02-05 2019-11-13 サノフイ 抗体−薬物複合体治療での使用のための免疫造影剤
WO2014180754A1 (en) * 2013-05-07 2014-11-13 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules
SG11201509259RA (en) * 2013-05-10 2015-12-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
KR102286053B1 (ko) 2013-06-26 2021-08-04 누맙 세러퓨틱스 아게 신규한 항체 기본구조
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP3307776A1 (en) * 2015-06-15 2018-04-18 Numab Innovation AG Hetero-dimeric multi-specific antibody format
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies

Also Published As

Publication number Publication date
AU2016278586B2 (en) 2022-05-19
JP2021087436A (ja) 2021-06-10
MA44381A (fr) 2019-01-23
CN115057936A (zh) 2022-09-16
JP7140861B2 (ja) 2022-09-21
WO2016202457A8 (en) 2017-11-30
CA2989474C (en) 2023-09-05
US20180355024A1 (en) 2018-12-13
US20220332797A1 (en) 2022-10-20
WO2016202457A1 (en) 2016-12-22
AU2022218544A1 (en) 2022-09-15
JP6839101B2 (ja) 2021-03-03
US11879005B2 (en) 2024-01-23
IL256314B (en) 2022-06-01
EP3307776A1 (en) 2018-04-18
JP2018522545A (ja) 2018-08-16
CN107922486B (zh) 2022-05-31
MX2022011472A (es) 2023-03-01
EP4047020A1 (en) 2022-08-24
IL293435A (en) 2022-07-01
AU2016278586A1 (en) 2018-01-04
EA201890041A1 (ru) 2018-07-31
JP2022177097A (ja) 2022-11-30
HK1245805A1 (zh) 2018-08-31
IL256314A (en) 2018-02-28
US11236150B2 (en) 2022-02-01
JP7457764B2 (ja) 2024-03-28
CA2989474A1 (en) 2016-12-22
KR20180012860A (ko) 2018-02-06
CN107922486A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
MX2022011472A (es) Formato de anticuerpo multiespecifico heterodimerico.
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
EP3461261A4 (en) PROTEINS BINDING TO THE VARIABLE MONOCATERARY FRAGMENT OF CD3
PH12017502180A1 (en) Tau-binding antibodies
EP3258959A4 (en) Antibody therapeutics that bind cd137
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
EP3416690A4 (en) SPECIFIC APTAMER
DK3142750T3 (da) Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
PH12017502207A1 (en) Tau-binding antibodies
IL280004A (en) Antibody molecules that bind PD-L1 and CD137
IL254239A0 (en) Modified antibodies that bind to transforming growth factor-beta-1 with high affinity, avidity and specificity
EP3689903A4 (en) FIBRONECTIN B DOMAIN BINDING PROTEIN
EP3807318A4 (en) MULTISPECIFIC ANTIBODY CONSTRUCTS
EP3554535A4 (en) PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3309169A4 (en) Antibody binding specifically to isolated vimentin-derived peptide, or binding fragment of the peptide
IL254238B (en) ß1 transforming growth factor binding dimers with high affinity, avidity and specificity
EP3368900A4 (en) Sandwich assay for small molecules
NZ731491A (en) Cd83 binding proteins and uses thereof
IL292799A (en) Antibodies against siglec-9
EP3464598A4 (en) APTAMER-BASED ANALYTICAL TESTS
EP3660155A4 (en) ANTI-CD147 ANTIBODY
EP3444273A4 (en) ANTIBODY BINDING SPECIFICALLY TO AIMP2-DX2 PROTEIN
EP3243837A4 (en) Bispecific antibody binding to trailr2 and psma
EP3583134A4 (en) NEW MULTI-SPECIFIC BINDING PROTEINS
GB201818283D0 (en) Antibody molecules that bind PD-L1 and CD137